代谢综合征新型治疗药物靶标的研究现状  

Novel potential therapeutic targets for metabolic syndrome treatment

作　　者：陈伟[1] 王莉莉[1] 李松[1] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850

出　　处：《中国新药杂志》2007年第22期1828-1833,共6页Chinese Journal of New Drugs

基　　金：国家863计划资助项目(2004AA235080)

摘　　要：代谢综合征(MS)是一组代谢紊乱性疾病的总称,近年来已成为严重威胁人类生活健康的新兴、高发性疾病。靶向MS病理生理过程关键环节,同时纠正多种代谢紊乱症状是MS新型治疗药物的研究方向。以往研究表明,过氧化物酶增殖体活化受体(Peroxisome proliferator-activated receptors,PPARs)α,β/δ和γ,11β-羟基类固醇脱氢酶1(11β-HSD1)、肝X受体(LXR)、大麻素受体1(CB1)等分子与MS(包括胰岛素抵抗、高血糖、肥胖、高脂血症、高血压、动脉粥样硬化等)的发生和发展过程密切相关,对其靶向干预最有可能有效纠正MS多种临床病理紊乱。现综述上述分子作为MS治疗药物潜在靶标的研究进展。Metabolic syndrome（ MS）, a constellation of metabolic dysfunctions associated with an increased risks for cardiovascular diseases and diabetes, is becoming increasingly common. Now, targeting on the key etiological factors and improving the multiple metabolic disorders simultaneously is a better strategy in developing novel candidate compounds. The peroxisome proliferator-activated receptors （ PPARs）, Cannabinoid receptor type 1 （ CB1 ）, 11 β-hydroxysteroid dehydrogenase 1 （ 11 β-HSD1 ） and liver X receptor（LXR） are closely related to the pathophysiologic process of MS which includes insulin resistance, central obesity, dyslipidemia, elevated blood pressure and atherosclerosis, etc, and are believed to be the prospective potential targets for MS. This paper mainly reviewed the progression of these potential targets.

关 键 词：代谢综合征 胰岛素抵抗 过氧化物酶增殖体活化受体 11Β-羟基类固醇脱氢酶1 大麻素受体1 肝X受体 

分 类 号：R977[医药卫生—药品]